Andrea Botticelli

Patients’ and oncologists’ perspectives on shared decision-making and treatment communication in HR+/HER2 − advanced breast cancer: a multicountry survey

Hormone receptor–positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) breast cancer (BC) represents approximately 70% of all cases. In locally advanced or metastatic stages (laBC/mBC), patients’ quality of life (QoL) often worsens, making shared decision-maki...

Cemiplimab in cutaneous squamous cell carcinoma: a longer follow‐up study focusing on the late toxicities

Summary Background and Objectives Cemiplimab was the first systemic therapy approved for advanced cutaneous squamous cell carcinoma (cSCC). Patients and Methods We report findings from the Italian early access program cohort, comprising 134 patients treated with cemiplimab, with...